Selective retina therapy with automatic real-time feedback-controlled dosimetry for chronic central serous chorioretinopathy in Korean patients

• Published in: Graefe's archive for clinical and experimental ophthalmology 2017-07, Vol.255 (7), p.1375-1383
• Main Authors: Park, Young Gun, Kang, Seungbum, Kim, Minhee, Yoo, Nari, Roh, Young Jung
• Format: Article
• Language: English
• Subjects: Acuity; Angiography; Central Serous Chorioretinopathy - diagnosis; Central Serous Chorioretinopathy - epidemiology; Central Serous Chorioretinopathy - surgery; Chronic Disease; Dosimetry; Energy; Feedback; Female; Fluorescein; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Laser Therapy - methods; Leakage; Male; Medical imaging; Medicine; Medicine & Public Health; Middle Aged; Ophthalmology; Prevalence; Republic of Korea - epidemiology; Retina; Retina - diagnostic imaging; Retina - surgery; Retinal Disorders; Retrospective Studies; Statistical analysis; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity; Visual perception
• ISSN: 0721-832X; 1435-702X
• DOI: 10.1007/s00417-017-3672-3

Purpose To evaluate the safety and efficacy of selective retina therapy (SRT) with real-time feedback-controlled dosimetry (RFD) in the treatment of chronic central serous chorioretinopathy (CSC). Methods In this retrospective case series study, 50 eyes of 49 patients with chronic CSC demonstrating focal or diffuse foveal leakages on fundus fluorescein angiography (FFA) were included. Following evaluation of test spots at temporal arcades, SRT (wavelength 527 nm, pulse repetition rate 100 Hz, pulse energy ramp with maximal 15 pulses) with retinal spot diameter of 200 μm was applied to the areas of each leakage observed on fluorescein angiography. Changes in mean best corrected visual acuity (BCVA), maximum macular thickness (MMT), subretinal fluid (SRF) height, and subfoveal choroidal thickness (SCT) were evaluated at 1, 2 and 3 months after treatment. RFD was used for adjusting the pulse energy. Eyes received a mean of 21.1 ± 18.1 treatment spots with a range of energies between 50uJ and 200uJ per pulse. Results Subretinal fluid (SRF) was completely resolved in 74% (37/50 eyes) at month 3. Mean BCVA (LogMAR) was improved from 0.44 ± 0.29 at baseline to 0.37 ± 0.32 at month 3 ( p  = 0.001). MMT was decreased from 335.0 ± 99.8 μm at baseline to 236.4 ± 66.4 μm after 3 months ( p